Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.33 |
| ▸ | ESRRG | P62508 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.32 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35210767 | 0.90 | TDP1 (0.41) | HRH3L3MBTL3L3MBTL1KDM2BOPRM1 | |
| SCHEMBL8720766 | 0.87 | HRH3 (0.38) | HRH3MGLL | |
| SCHEMBL8720752 | 0.83 | MEN1 (0.38) | HRH3L3MBTL1MEN1KMT2A | |
| SCHEMBL30908873 | 0.83 | HRH3 (0.39) | HRH3L3MBTL3L3MBTL1KDM2BOPRM1 | |
| SCHEMBL30909167 | 0.82 | HRH3 (0.38) | HRH3L3MBTL1OPRM1OPRK1KMT2A | |
| SCHEMBL35211302 | 0.81 | HRH3 (0.32) | HRH3 | |
| SCHEMBL8721871 | 0.80 | HRH3 (0.40) | HRH3L3MBTL3L3MBTL1KDM2BOPRM1 | |
| SCHEMBL8724259 | 0.79 | HRH3 (0.39) | HRH3L3MBTL3L3MBTL1ESRRGOPRM1 | |
| SCHEMBL8720711 | 0.79 | TP53 (0.44) | MEN1KMT2A | |
| SCHEMBL8725926 | 0.78 | TDP1 (0.41) | L3MBTL3L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| WO-2024073845-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2024-04-11 | — | — | WO | disclosed |
| EP-0875513-A1 | Substituted heteroaromatic 5-HT 1F agonists | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | HRH3 126/4885L3MBTL3 674/4885L3MBTL1 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.